Contact Information

bmi_logodreamstime_2122395

Biological Mimetics, Inc.
124 Byte Drive
Frederick, MD 21702

Phone: (301) 620-7565
Fax: (301) 620-1827
General E-mail: info at bmi-md.com  
Science and Technology: tobin at bmi-md.com
Business Development: chaudhuri at bmi-md.com

 

Get Directions!



Interactive Weather

48°
°F | °C
Clear
Humidity: 76%
Wind: S at 5 mph
Wed
Mostly Sunny
41 | 62
5 | 16
Thu
Mostly Sunny
45 | 64
7 | 17
Fri
Chance of Showers
32 | 68
0 | 20

Search Site

Virus Developments

BMI is developing an AIDS vaccine and applying its Immune Dampening and Refocusing Technology to the outer HIV envelope glycoprotein gp120/gp41, which is the main mediator of viral fusion and entry with host receptors CD4 and chemokine receptors CCR5 and/or CXCR4.

The Latest Technology

Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of public health through the application of novel technologies for the development and commercialization of human and veterinary biologics to address a long list of hitherto intractable disease targets involving viruses, bacteria, parasites, and cancer.

Research & Development

pone_0020130_g003Globally, influenza is responsible for 250,000 to 500,000 deaths annually and is considered one of the most important respiratory pathogens of humans. In the majority of the past ten years, H3N2 has dominated in prevalence of infection and disease over H1N1, H2N2, and influenza B. In the United States alone, approximately 5–20% of the population contracts influenza illnesses leading to about 240,000 hospitalizations and 40,000 deaths with the majority due to H3N2. In addition to morbidity and mortality, influenza causes an annual economic impact in the range of $80B in this country alone. Click here to learn more .

Company News

blk triangleJune 2011: BMI announces collaborative research agreement with Crucell-BV for development of a universal influenza vaccine
blk triangleNov. 2010: BMI announces collaborative research agreement with GSK-Biologicals for development of an immune refocused vaccine for respiratory infection
blk triangleSept 2010: BMI is awarded a Qualifying Therapeutic Discovery Project Award
blk triangleJune 2010: BMI is awarded a Small Business Innovative Research Grant from the NIH for vaccine development
blk triangleNov. 2009: BMI is a prime contractor in the Fundamentals of Biology Program of DARPA/DSO for the study of modularity in biological systems
blk triangleMay 2008: BMI is awarded a subcontract for HIV vaccine development through the Henry M Jackson Institute for the Advancement of Military Medicine.
blk triangleJuly 2007: BMI is awarded a subcontract from DARPA through Rice University to study the evolution of pathogens
blk triangleJune 2007: BMI is awarded a subcontract from DARPA through VaxDesign (Orlando, Florida) to study immunogenicity of influenza